Health Care • Biotechnology: Pharmaceutical Preparations
$4.77 ▲ +0.26
(+5.77%)
MKT CAP: $7.0M • VOL: 46.4K
52W L $2 52W H $11
ROARABLE / RQD
D • 48/100
PIOTROSKI
1 / 9
CNSP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.0M | -$14.9M | -$18.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$16.0K | -$14.9K | -$18.9K |
| EBITDA (Normalized) | -$16.0M | -$14.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.8M | -$17.1M | -$14.1M |
| Capital Expenditures (CapEx) | $18.2K | $4.2K | — |
| Free Cash Flow (FCF) | -$13.8M | -$17.1M | -$14.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.2M | $6.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.5M | $6.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CNSP.